**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 84561

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Emergency exploratory laparotomy and radical gastrectomy in patients with gastric cancer combined with acute upper gastrointestinal bleeding**

Kuang F *et al*. GC patients combined with acute UGIB

Feng Kuang, Jian Wang, Bai-Qi Wang

**Feng Kuang, Jian Wang,** Department of Emergency, The First Affiliated Hospital of University of South China, Hengyang 421001, Hunan Province, China

**Bai-Qi Wang,** Department of Radiation Oncology, The Second Affiliated Hospital of University of South China, Hengyang 421001, Hunan Province, China

**Author contributions:** Wang J designed the study; Kuang F and Wang BQ performed the experiments and analyzed the data; Kuang F wrote the manuscript; and all authors have read and approved the final manuscript.

**Corresponding author: Jian Wang, MM, Attending Doctor,** Department of Emergency, The First Affiliated Hospital of University of South China, No. 69 Chuanshan Road, Hengyang 421001, Hunan Province, China. wangjian13988@163.com

**Received:** April 6, 2023

**Revised:** May 7, 2023

**Accepted:** May 24, 2023

**Published online:** July 27, 2023

**Abstract**

BACKGROUND

Gastric cancer (GC) is a prevalent malignant tumor worldwide and ranks as the fourth leading cause of cancer-related mortality. Upper gastrointestinal bleeding (UGIB) is a frequent complication of GC. Radical gastrectomy and palliative therapy are widely used surgical procedures in the clinical management of GC. This study intends to probe the clinical efficacy and safety of radical gastrectomy and palliative therapy on the basis of exploratory laparotomy in patients with GC combined with UGIB, hoping to provide valuable information to aid patients in selecting the appropriate surgical intervention.

AIM

To investigate the clinical efficacy and safety of exploratory laparotomy + radical gastrectomy and palliative therapy in patients with GC and UGIB combined.

METHODS

A total of 89 GC patients admitted to the First Affiliated Hospital of the University of South China between July 2018 and July 2020 were selected as participants for this study. The 89 patients were divided into two groups: radical resection group (*n* = 46) treated with exploratory laparotomy + radical gastrectomy and Palliative group (*n* = 43) treated with palliative therapy. The study compared several variables between the two groups, including surgical duration, intraoperative blood transfusion volume, postoperative anal exhaust time, off-bed activity time, length of hospitalization, and incidence of complications such as duodenal stump rupture, anastomotic obstruction, and postoperative incision. Additionally, postoperative immune function indicators (including CD3+, CD4+, CD8+, CD4+/CD8+, and CD3+/HLADR+), immunoglobulin (IgG and IgM), tumor markers (CEA, CA199, and CA125), and inflammatory factors (IL-6, IL-17, and TNF-α) were assessed. The surgical efficacy and postoperative quality of life recovery were also evaluated. The patients were monitored for survival and tumor recurrence at 6 mo, 1 year, and 2 years post-surgery.

RESULTS

The results indicated that the duration of operation time and postoperative hospitalization did not differ between the two surgical procedures. However, patients in the radical resection group exhibited shorter intraoperative blood loss, anus exhaust time, off-bed activity time, and inpatient activity time than those in the Palliative group. Although there was no substantial difference in the occurrence of postoperative complications, such as duodenal stump rupture and anastomotic obstruction, between the radical resection group and Palliative group (*P* > 0.05), the radical resection group exhibited higher postoperative immune function indicators (including CD3+, CD4+, CD8+, *etc.*) and immunoglobulin levels (IgG, IgM) than the Palliative group, while tumor markers and inflammatory factors levels were lower than those in the radical resection group. Additionally, surgical efficacy, postoperative quality of life, and postoperative survival rates were higher in patients who underwent radical gastrectomy than in those who underwent palliative therapy. Moreover, the probability of postoperative tumor recurrence was lower in the radical gastrectomy group compared to the palliative therapy group, and these differences were all statistically significant (*P* < 0.05).

CONCLUSION

Compared to palliative therapy, exploratory laparotomy + radical gastrectomy can improve immune function, reduce the levels of tumor markers and inflammatory factors, improve surgical efficacy, promote postoperative quality of life recovery, enhance survival rates, and attenuate the probability of tumor recurrence.

**Key Words:** Gastric cancer; Exploratory laparotomy; Radical gastrectomy; Upper gastrointestinal bleeding; Safety

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Kuang F, Wang J, Wang BQ. Emergency exploratory laparotomy and radical gastrectomy in patients with gastric cancer combined with acute upper gastrointestinal bleeding. *World J Gastrointest Surg* 2023; 15(7): 1423-1433

**URL:** https://www.wjgnet.com/1948-9366/full/v15/i7/1423.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v15.i7.1423

**Core Tip:** Gastric cancer (GC) is a prevalent digestive system malignancy that commonly results in upper gastrointestinal bleeding (UGIB). Surgery is the primary treatment modality for GC. Radical gastrectomy and palliative therapy are commonly adopted surgical procedures. This present study investigated the clinical efficacy and safety of palliative therapy and exploratory laparotomy + radical gastrectomy in patients with GC and acute UGIB. The outcomes of the study showed that exploratory laparotomy + radical gastrectomy improved surgical efficacy, enhanced survival rates, lowered the probability of tumor recurrence, and bettered the prognosis of patients.

**INTRODUCTION**

Gastric cancer (GC) is a prevalent malignant tumor of the digestive system and ranks as the fourth leading cause of cancer-related death[1]. The most common histological type of GC is gastric adenocarcinoma, which is classified into papillary adenocarcinoma, tubular adenocarcinoma, minimal differentiation adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma, based on various histological structures[2,3]. Early GC is typically asymptomatic or accompanied by mild symptoms in clinical practice. However, when symptoms become noticeable, the lesions are frequently in the middle or advanced stages[4,5]. Therefore, it is critical to enhance the early diagnosis rate of GC and deliver prompt treatment to ensure the prognosis of patients and increase their survival rate.

Currently, surgery is the primary treatment method for patients with GC and is key to improving survival rates[6]. The choice of surgical methods depends on the patient’s physical condition and tumor condition. Radical gastrectomy and palliative therapy are extensively used surgical procedures for the treatment of GC in clinical practice. Radical gastrectomy is a surgical procedure in which the primary lesion of malignant tumors and peripheral infected tissues are removed along with the entire stomach and lymph nodes in the surrounding lymphatic drainage area, with the aim of achieving radical treatment[7,8]. It has been reported to be safe and feasible in elderly patients, with short-term complication and long-term survival rates similar to those in non-elderly patients[9]. Palliative therapy is a surgery performed when the tumor has already spread locally or metastasized distantly, and it is precisely known before or during surgery that the tumor lesion cannot be completely removed[10,11]. For patients with middle or advanced GC who have surgical indications, palliative therapy can improve relevant symptoms and prolong survival time, promoting improvement in quality of life[12]. Nevertheless, D2 lymphadenectomy is not performed during palliative therapy, which requires dissociation and elimination of the tumor cells, resulting in damaged small blood vessels on the tumor cells to a certain extent and thus augmented intraoperative blood loss. This is particularly harmful to patients with GC who also have upper gastrointestinal bleeding (UGIB)[13,14]. Furthermore, due to decreased physical function, many patients may have reduced tolerance for exploratory laparotomy and radical surgery, which can adversely affect the therapeutic effect[15,16]. It is crucial to select an appropriate and reasonable surgical procedure for GC patients, particularly those with complications.

This retrospective study analyzed the clinical data of 89 GC patients at the hospital to explore the efficacy and safety of palliative therapy and radical gastrectomy in treating patients with GC and acute UGIB on the basis of exploratory laparotomy, in the hope of providing valuable insights for treating GC patients.

**MATERIALS AND METHODS**

***General information***

The study subjects comprised 89 patients with GC who were admitted to The First Affiliated Hospital of the University of South China between July 2018 and July 2020. The Ethics Committee of The First Affiliated Hospital of the University of South China approved this study. The 89 patients with GC were divided into two groups based on the surgical methods used: The radical resection group underwent radical gastrectomy (*n* = 46), while the palliative group received palliative therapy (*n* = 43). No significant differences were found in the general characteristics of the patients (*P* > 0.05), indicating comparability (see Table 1).

***Inclusion and exclusion criteria***

Inclusion criteria were as follows: (1) Patients diagnosed with GC *via* pathological biopsy; (2) Patients without other serious diseases; (3) Patients without mental disorders; (4) Patients with surgical indications, including the absence of severe cardiopulmonary dysfunction or coagulation disorders, tolerance to anesthesia and surgical conditions, and feasibility of surgical treatment confirmed by imaging evaluation; and (5) Patients with upper gastrointestinal bleeding.

Exclusion criteria: (1) Patients with other serious diseases; and (2) Patients with serious mental diseases or communication disorders.

***Method***

Upon admission, patients in both groups underwent thorough preoperative preparation for standard care. Patients in the palliative group undergoing palliative therapy were initially positioned supine and provided with general anesthesia. A midline incision was made on the upper abdomen, followed by an exploratory laparotomy to assess the location, size, and metastasis of the tumor. Based on the specific condition of each patient, they were then subjected to resection surgery (*e.g.*, proximal gastrectomy, distal gastrectomy, *etc.*) or non-resection surgery[17].

Patients in the radical resection group underwent radical gastrectomy, using the same anesthesia and exploratory laparotomy techniques as the palliative group. The posterior peritoneum was incised from the lateral side of the patient’s duodenum, and D2 lymphadenectomy was used to dissect their lymph nodes. Following dissection, patients received a specific surgical intervention depending on their condition: Total gastrectomy for lesions larger than 4 cm, proximal gastrectomy for patients with gastric body and cardia tumors, cardia ulcers with bleeding, perforation or portal hypertension resulting in esophageal variceal rupture and bleeding at the bottom of the stomach; or distal gastrectomy for patients with GC and massive serosal invasion, tumor diameter larger than 10 cm, or lymph node metastases fused and surrounded important blood vessels or extensively infiltrated surrounding tissues[18].

***Observational indicators***

**Observation and recording of the patient’s operation time, intraoperative blood transfusion volume, postoperative hospitalization duration, and other indicators in the two groups:** Gastrointestinal metastasis and bleeding are common in patients with GC, and surgeries for these patients often take a long time. In cases where intraoperative bleeding exceeds 1000 mL, patients may experience a significant reduction in vital signs, necessitating timely blood transfusions. Operation time was defined as the period between the beginning of exploratory laparotomy and the end of surgery. The volume of blood transfused throughout the operation was also recorded. Postoperative hospitalization duration was defined as the time from postoperative transfer to the ward to the patient’s rehabilitation and discharge from the hospital and was measured alongside off-bed activity and anal exhaust time.

**Observation and recording of the patient’s overall incidence rate of postoperative complications in the two groups:** Postoperative complications of GC are primarily associated with patients’ physical conditions and surgical procedures[7,19]. These complications include postoperative bleeding, which is typically characterized by the drainage of small amounts of dark red or brown gastric fluid after surgery, duodenal stump rupture that manifests as acute and severe pain with peritoneal irritation in the right upper abdomen, and anastomotic obstruction, which presents as vomiting after meals or bile-free vomiting. Other possible complications following GC surgery encompass intestinal obstruction, abdominal effusion, reflux gastritis, incision infection, and bleeding. All the postoperative complications were observed, recorded, and divided by the total case numbers to obtain the overall incidence rate of complications.

**Observation of the patient’s postoperative immune function indicators:** We collected 4 mL of venous blood from patients in the two groups 12 wk before and after the surgery. CD3+, CD4+, CD8+, CD4+/CD8+, and CD3+/HLADR+ were detected through flow cytometry, Epics. XLII flow cytometry was harnessed for the assay, the parameters of flow cytometry were set, a 15-mW fluoride laser with 488 nm long was adopted as the excitation light source, immunofluorescence data were analyzed *via* Exp032 ADC, and DNA cell cycle was fitted and analyzed by Muticycle AV software. In addition, immunoglobulin (IgG, IgM) levels were gauged using immunonephelometry.

**Observation of the patient’s levels of tumor markers and inflammatory factors after the operation:** Fasting venous blood (3 mL) was harvested 12 wk before and after surgery from patients in the two groups. Serum was separated and analyzed for levels of carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and carbohydrate antigen 125 (CA125) using chemiluminescence. Additionally, interleukin (IL)-6, IL-17, and tumor necrosis factor α (TNF-α) were detected *via* enzyme-linked immunosorbent assay, in strict adherence to the manufacturer’s instructions[5,20].

**Observation of the patient’s surgical efficacy and postoperative quality of life recovery in the two groups:** Efficacy was evaluated 6 mo following surgery employing the RECIST1.1 Response Evaluation Criteria in Solid Tumors[21]. Complete response (CR) was defined as the complete disappearance of all lesions for at least 4 wk. Partial response (PR) refers to a reduction of lesion size by more than 30% and lasting for at least 4 wk. Stable disease (SD) represents a reduction in lesion size of less than 30% or an increase in size of up to 20%. Progressive disease (PD) was defined as a 20% or greater increase in the size of one or more lesions or the appearance of new lesions. Objective response rate (ORR) = (CR + PR)/number of patients in this group × 100%, disease control rate (DCR) = (CR + PR + SD)/number of patients in this group × 100%.

KPS scoring criteria[22,23] were exploited to evaluate the patient’s quality of life after surgery. Improvement was defined as an increase in score by more than 10 points after treatment compared to the score before treatment. Stability was regarded as a change in score of no more than 10 points after treatment, and ineffectiveness as a decrease in score by more than 10 points after treatment. Based on the score, patients’ quality of life was classified into one of three categories: improvement, stability, or ineffectiveness, to determine the recovery rate of their quality of life.

**Observation of the patient’s survival rate and tumor recurrence probability at 6 mo, 1 year and 2 years after the operation:** The survival rate and probability of tumor recurrence for patients were monitored at 6, 12, and 24 mo for the purpose of the overall comprehension and tracking of the patient’s disease recovery. The postoperative survival rate and tumor recurrence rate were observed and analyzed.

***Statistical analysis***

The data for this study were processed and analyzed using SPSS 21.0 software. The measurement data were presented as mean ± SD, and group comparisons were performed using the *t*-test. Enumeration data were expressed as *n* (%). The*χ*2 test was used for comparison. Differences were considered statistically significant at *P* < 0.05.

**RESULTS**

***Comparison of the patients’ surgical indicators between the two groups***

Various intraoperative and postoperative indicators, such as operation time, intraoperative blood transfusion volume, and postoperative hospitalization duration time, were observed in the two groups for different surgical methods. It was found that the patients’ intraoperative blood transfusion volume in the exploratory laparotomy + radical gastrectomy group was less than that in the palliative group. Furthermore, patients in the radical resection group had earlier off-bed activity and anus exhaust time. The differences had statistical significance (*P* < 0.05). However, there was no significant difference in operation time and postoperative hospitalization duration time between the two groups (*P* > 0.05). These findings unraveled that exploratory laparotomy + radical gastrectomy could reduce intraoperative blood transfusion volume and accelerate postoperative off-bed activity and anus exhaust, while radical gastrectomy did not affect the patient’s recovery time (Table 2).

***Comparison of the patients’ incidence rate of postoperative complications between the two groups***

Postoperative bleeding, duodenal stump rupture, anastomotic obstruction, intestinal obstruction, abdominal effusion, reflux gastritis, incision infection, and other complications were observed in the two groups that received different surgical treatments. The overall incidence rate of postoperative complications was not remarkably different between the two groups that received palliative therapy or laparotomy + radical gastrectomy, and the difference held no statistical significance (*P* > 0.05). This suggested that the procedure of exploratory laparotomy + radical gastrectomy was safe and manageable (Table 3).

***The patients’ postoperative immune function in the two groups***

The study discovered no substantial differences in the levels of CD3+, CD4+, CD8+,and CD4+/CD8+ prior to operation between the radical resection and palliative groups (*P* > 0.05). Nevertheless, subsequent to the operation, CD3+, CD4+, CD3+/HLADR+,and CD4+/CD8+ levels were notably higher in the radical resection group than in the palliative group (*P* < 0.05). Furthermore, CD8+ levels in the palliative group after surgery were higher than before treatment (*P* < 0.05). Additionally, postoperative levels of IgG and IgM in the radical resection group were substantially increased to 18.35 ± 2.16 and 3.87 ± 0.53, respectively, which were significantly higher than the 14.68 ± 2.28 and 3.56 ± 3.19 levels in the palliative group. The difference was regarded as statistically significant (*P* < 0.05). This finding suggested that the exploratory laparotomy + radical gastrectomy procedure could dramatically improve the patient’s immune function (Table 4).

***Comparison of the levels of postoperative tumor markers and inflammatory factors between the two groups***

The outcomes revealed no noticeable difference in tumor markers CEA, CA199, and CA125 between the two groups prior to the operation (*P* > 0.05). However, at 12 wk after the operation, the levels of tumor markers were significantly lower in both groups, with a greater decrease observed in the radical gastrectomy group (*P* < 0.05). Specifically, the levels of CEA, CA199, and CA125 in the two groups were 7.72 ± 0.72 (ng/mL), 18.57 ± 3.15 (U/mL), and 34.34 ± 3.66 (U/mL), respectively. Similarly, there was no substantial difference in the levels of serum inflammatory factors IL-6, IL17, and TNF-α between the groups before surgery (*P* > 0.05). However, the levels of serum inflammatory factors IL-6, IL-17, and TNF-α were 27.47 ± 2.59 (pg/mL), 43.14 ± 5.69 (pg/mL), and 5.579 ± 0.46 (pg/mL), respectively, at 12 wk after the operation, which were lower than those before treatment with a greater decrease observed in the radical gastrectomy group (*P* < 0.05). This finding confirmed that exploratory laparotomy + radical gastrectomy could considerably attenuate inflammatory reactions, while both surgical methods could vigorously enhance the levels of tumor markers, controlled tumor factors, and inflammatory factors. Moreover, the radical gastrectomy group exhibited more evident improvement than the palliative therapy group (Table 5).

***Comparison of surgical efficacy and postoperative quality of life between the two groups***

The research discovered an increase in ORR and DCR in the radical resection group as opposed to the palliative group, and the difference had statistical significance (*P* < 0.05). Besides, the recovery of living quality was observed in the two groups undergoing various treatment methods. After the surgery, it was observed that the rate of improvement of patient’s quality of life was 50% for the radical resection group, and the effective rate was 80.43%. In comparison, the rate of improvement of patient’s quality of life in the palliative group was 23.26%, and the effective rate was 58.14%. The data for the radical resection group was higher than that of the palliative group, and the difference contained statistical significance (*P* < 0.05). This denoted that exploratory laparotomy + radical gastrectomy could enhance the rate of disease control and improve patients’ quality of life after surgery (Table 6).

***Comparison of the patient’s postoperative survival rate and tumor recurrence rate between the two groups***

The survival and tumor recurrence rates were evaluated at 6 mo, 1 year, and 2 years post-operation. The findings demonstrated that the survival rate at 6 mo, 1 year, and 2 years after laparotomy + radical gastrectomy was 100%, 97.83%, and 86.96%, respectively, and the differences had statistical significance (*P* < 0.05). After 6 mo of follow-up, it was discovered that there existed no substantial difference in tumor recurrence rates between the two groups that received different surgeries (*P* > 0.05). Nevertheless, after 1 and 2 years of follow-up, the tumor recurrence rate of patients undergoing exploratory laparotomy + radical gastrectomy was lower than that of patients undergoing palliative therapy, and the difference was deemed to be statistically significant (*P* < 0.05). This finding indicated that exploratory laparotomy + radical gastrectomy could improve the postoperative survival rate of patients and decrease the tumor recurrence rate (Table 7).

**DISCUSSION**

Previous studies have shown that the peak incidence of GC is around the age of 60 years, and patients often have a variety of chronic systemic diseases, which can complicate clinical treatment[20,24]. Surgery remains the mainstay of treatment and has been shown to improve patients’ five-year post-treatment survival rate[25-27]. However, given the differences in physical function among patients, choosing an appropriate surgical procedure is crucial to improve prognosis.

Prior studies suggest that patients with GC have relatively low malignant tumor cell degree, and radical gastrectomy should be selected as far as possible under the premise of adapting to surgery, which can effectively improve the survival rate and prolong the survival time of patients[28,29]. However, radical gastrectomy involves extensive clearance and can cause significant trauma, making it unsuitable for elderly patients with poor physical condition. Palliative therapy, on the other hand, can alleviate clinical symptoms quickly and reduce surgical risk[17,30,31]. Therefore, we compared different patient indicators following various surgical procedures to identify a suitable approach for patients and improve postoperative recovery and quality of life.

In this research, a total of 89 patients who underwent either exploratory laparotomy + radical gastrectomy or palliative therapy were included. The study revealed that patients who underwent exploratory laparotomy + radical gastrectomy required significantly less intraoperative blood transfusion. This is likely because palliative therapy involves dealing with a large number of small vessels at the tumor separation interface, while radical gastrectomy, which combines gastrectomy and D2 lymphadenectomy, can protect vascular branches and reduce intraoperative blood loss during lesion resection in patients with GC[32,33]. Additionally, there was no difference in hospitalization duration between the two surgical procedures, suggesting that exploratory laparotomy + radical gastrectomy did not cause greater harm to patients or hinder their recovery. Bleeding, perforation, and pyloric obstruction are common complications following GC surgery[34]. However, this study found no significant difference in the overall incidence of complications such as obstruction, reflux gastritis, and incision infection between patients who underwent exploratory laparotomy + radical gastrectomy and those who received palliative therapy. Moreover, the postoperative off-bed activity time and anus exhaust time were earlier than those of patients who underwent palliative therapy, which reduced the likelihood of postoperative incision infection and ensured that overall surgical safety remained within the controllable range.

Studies have shown that postoperative tissue injury can lead to the release of immunosuppressive agents, which may slow down the progression of tumor diseases[35]. Here, we aimed to investigate the impact of two different surgical procedures on the immune function of patients with GC. We discovered that tissue injury caused by radical gastrectomy and palliative therapy had a certain impact on the immune function of patients. However, immune factors such as CD3+, CD4+, and CD8+ and immune proteins such as IgG and IgM were vigorously boosted subsequent to exploratory laparotomy + radical gastrectomy by contrast to patients undergoing palliative therapy, and these improved indicators reflected the recovery of T lymphocyte function and the enhancement of body resistance ability in patients were conducive to promoting the cellular immune function of patients. This may be related to early postoperative enteral nutrition support in patients undergoing radical gastrectomy for GC, which is superior to parenteral nutrition, regulates the metabolic and immune function of the body, corrects the immunosuppression triggered by surgical trauma, and improves the prognosis[8,36].

CA199 is a macromolecular glycoprotein that contains mucinous components, and its level is correlated with tumor size, lymph node metastasis, and depth of invasion. It is an independent prognostic indicator for GC patients, with high levels in the serum indicating shortened survival time[37]. Similarly, CEA is a polysaccharide-rich protein complex and a carcinoembryonic antigen produced during embryonic and fetal stages. It has prognostic significance for GC and is associated with progressive poorly differentiated adenocarcinoma, tumor size, serosal surface invasion, and lymph node metastasis[38]. Furthermore, CA125, a glycoprotein tumor-associated antigen, has great clinical value in the diagnosis of ovarian cancer and shows positive reactions in other malignant tumors, such as GC, cervical cancer, and breast cancer[39]. We detected the levels of these tumor markers and found that the levels were higher in patients before radical gastrectomy and palliative therapy but significantly lower in both groups at 12 wk after surgery. CEA, CA199, CA125, and other markers significantly improved in patients who underwent exploratory laparotomy + radical gastrectomy compared to those in the palliative therapy group. Moreover, the levels of inflammatory factors were significantly lower than those in the palliative therapy group, suggesting that radical gastrectomy could ameliorate the tumor, control the enhancement of tumor factors, and heighten the level of inflammation. This finding has high clinical application value.

Adenocarcinoma is the primary pathological type in patients with GC, while poorly differentiated adenocarcinoma is infrequent. Hence, clinical exploratory laparotomy + radical gastrectomy can prolong the survival time of patients. Additionally, this study found that radical gastrectomy did not increase operative mortality despite being more traumatic[40,41]. Du *et al*[42] also found that radical gastrectomy was performed to thoroughly dissect lymph nodes and other debris to eliminate the risk of residual and recurrent lesions. The outcomes of this research showed that the survival rates of follow-up at 6 mo, 1 year, and 2 years in the radical resection group were significantly higher than those in the palliative group. The surgical efficacy was significantly better than that of the palliative group, and the postoperative quality of life was significantly improved compared with that of the palliative group, which indicated that exploratory laparotomy + radical gastrectomy could effectively prolong the survival time of patients, improve the survival rate and significantly improve their quality of life compared with palliative therapy. It was consistent with the results of previous studies[43,44]. More of note, the recurrence rate of tumors at 1 and 2 years of follow-up was significantly lower in patients who underwent exploratory laparotomy + radical gastrectomy than in the palliative group. This finding highlighted the potential benefits of exploratory laparotomy + radical gastrectomy, which can improve postoperative quality of life, reduce tumor recurrence, and improve patient prognosis.

To summarize, patients with GC should carefully choose their treatment options due to their unique circumstances. This study concludes that exploratory laparotomy + radical gastrectomy boasts significant therapeutic benefits. Compared with palliative therapy, it effectively improves surgical efficacy and immune function, reduces levels of tumor markers and inflammatory factors, prolongs survival, and improves the quality of life while reducing tumor recurrence rates with controllable safety. This treatment should be widely applied while ensuring strict adherence to indications. However, the retrospective nature of this study limited its scope and design. The 2-year survival rate observation was relatively short, and long-term survival status could not be assessed. Future studies should employ a more rigorous and systematic design to supplement and confirm these findings.

**CONCLUSION**

Laparotomy + radical gastrectomy is a preferable treatment over palliative therapy for GC patients suffering from upper digestive hemorrhage. It can enhance surgical efficacy, improve immune function, reduce tumor markers and inflammatory factors levels, prolong patient survival, improve quality of life, and lower the recurrence rate with controllable safety. The treatment is appropriate for patients with appropriate medical conditions.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is a malignant tumor that originates from the gastric mucosal epithelium, and it has the highest incidence rate among various malignant tumors in China. Surgery is the main clinical treatment for GC.

***Research motivation***

The incidence rate of GC is extremely high, and surgical treatment is the primary approach to curing this disease.

***Research objectives***

This study aims to explore the clinical value of giving radical surgery and palliative surgery based on exploratory laparotomy in patients with GC combined with upper gastrointestinal bleeding.

***Research methods***

A total of 89 GC patients were selected and divided into two groups - the palliative group and the radical resection group. The two groups were compared in terms of various indicators such as the operation time, intraoperative blood transfusion, postoperative anal exhaust time, bed time, duodenal stump rupture, anastomotic obstruction complications, and the postoperative immune function, immunoglobulin and tumor markers, inflammatory factors, surgical effect, postoperative quality of life recovery, as well as patient monitoring for postoperative survival and tumor recurrence.

***Research results***

The radical resection group had shorter intraoperative blood loss and anal exhaust time compared to the palliative group, but did not show a significant difference in the occurrence of postoperative complications. Additionally, the postoperative immune function index and immunoglobulin levels of the radical resection group were higher than those of the palliative group, while the levels of tumor markers and inflammatory factors were lower in the radical resection group. The surgical efficacy and postoperative quality of life of the radical resection group were also higher than those of the palliative group, and the postoperative survival rate was also higher for the radical resection group.

***Research conclusions***

Laparotomy combined with radical surgery can result in a shorter postoperative hospital stay, improved immune function, increased surgical efficacy, enhanced quality of life recovery, higher survival rate, and reduced chance of tumor recurrence.

***Research perspectives***

Due to the particularity of GC patients, they must be careful in selecting their treatment approach. Laparotomy combined with radical surgery can effectively enhance surgical efficacy, improve immune function, reduce tumor recurrence rate, and provide a safe and controllable treatment option. Therefore, this approach is worth promoting and applying. On the premise of strictly controlling the indications, laparotomy combined with radical surgery should be selected whenever possible.

**REFERENCES**

1 **Wei L**, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, Xu Y, Shen Y, Yang M. Noncoding RNAs in gastric cancer: implications for drug resistance. *Mol Cancer* 2020; **19**: 62 [PMID: 32192494 DOI: 10.1186/s12943-020-01185-7]

2 **Liu H**, Qu Y, Zhou H, Zheng Z, Zhao J, Zhang J. Bioinformatic analysis of potential hub genes in gastric adenocarcinoma. *Sci Prog* 2021; **104**: 368504211004260 [PMID: 33788653 DOI: 10.1177/00368504211004260]

3 **Tan Z**. Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review. *Med Sci Monit* 2019; **25**: 3537-3541 [PMID: 31080234 DOI: 10.12659/MSM.916475]

4 **Digklia A**, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. *World J Gastroenterol* 2016; **22**: 2403-2414 [PMID: 26937129 DOI: 10.3748/wjg.v22.i8.2403]

5 **Lee YC**, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology* 2016; **150**: 1113-1124.e5 [PMID: 26836587 DOI: 10.1053/j.gastro.2016.01.028]

6 **Argillander TE**, Festen S, van der Zaag-Loonen HJ, de Graeff P, van der Zaag ES, van Leeuwen BL, Nagengast WB, Verhage RJJ, Ruurda JP, van Munster BC, van Duijvendijk P. Outcomes of surgical treatment of non-metastatic gastric cancer in patients aged 70 and older: A systematic review and meta-analysis. *Eur J Surg Oncol* 2022; **48**: 1882-1894 [PMID: 35599137 DOI: 10.1016/j.ejso.2022.05.003]

7 **Guerrini GP**, Esposito G, Magistri P, Serra V, Guidetti C, Olivieri T, Catellani B, Assirati G, Ballarin R, Di Sandro S, Di Benedetto F. Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis. *Int J Surg* 2020; **82**: 210-228 [PMID: 32800976 DOI: 10.1016/j.ijsu.2020.07.053]

8 **Cheng Y**, Zhang J, Zhang L, Wu J, Zhan Z. Enteral immunonutrition versus enteral nutrition for gastric cancer patients undergoing a total gastrectomy: a systematic review and meta-analysis. *BMC Gastroenterol* 2018; **18**: 11 [PMID: 29338698 DOI: 10.1186/s12876-018-0741-y]

9 **Swierz MJ**, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Percutaneous ethanol injection for liver metastases. *Cochrane Database Syst Rev* 2020; **2**: CD008717 [PMID: 32017845 DOI: 10.1002/14651858.CD008717.pub3]

10 **Tey J**, Soon YY, Koh WY, Leong CN, Choo BA, Ho F, Vellayappan B, Lim K, Tham IW. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. *Oncotarget* 2017; **8**: 25797-25805 [PMID: 28445941 DOI: 10.18632/oncotarget.15554]

11 **Chen K**, Wang X, Yang L, Chen Z. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. *Cancer Control* 2021; **28**: 1073274821997430 [PMID: 33618535 DOI: 10.1177/1073274821997430]

12 **Bian SB**, Shen WS, Xi HQ, Wei B, Chen L. Palliative Therapy for Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer: A Meta-analysis Comparison of Gastrojejunostomy with Endoscopic Stenting. *Chin Med J (Engl)* 2016; **129**: 1113-1121 [PMID: 27098799 DOI: 10.4103/0366-6999.180530]

13 **Lau CHY**, Wu X, Chung VCH, Liu X, Hui EP, Cramer H, Lauche R, Wong SYS, Lau AYL, Sit RWS, Ziea ETC, Ng BFL, Wu JCY. Acupuncture and Related Therapies for Symptom Management in Palliative Cancer Care: Systematic Review and Meta-Analysis. *Medicine (Baltimore)* 2016; **95**: e2901 [PMID: 26945382 DOI: 10.1097/MD.0000000000002901]

14 **Martella L**, Bertozzi S, Londero AP, Steffan A, De Paoli P, Bertola G. Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. *Medicine (Baltimore)* 2015; **94**: e1113 [PMID: 26252272 DOI: 10.1097/MD.0000000000001113]

15 **Pan Y**, Chen K, Yu WH, Maher H, Wang SH, Zhao HF, Zheng XY. Laparoscopic gastrectomy for elderly patients with gastric cancer: A systematic review with meta-analysis. *Medicine (Baltimore)* 2018; **97**: e0007 [PMID: 29465537 DOI: 10.1097/MD.0000000000010007]

16 **Wagner AD**, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev* 2017; **8**: CD004064 [PMID: 28850174 DOI: 10.1002/14651858.CD004064.pub4]

17 **Zheng C**, Gao ZM, Huang HB, Li K, Liu XF. Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis. *Eur Rev Med Pharmacol Sci* 2021; **25**: 2299-2312 [PMID: 33755967 DOI: 10.26355/eurrev\_202103\_25262]

18 **Zizzo M**, Zanelli M, Sanguedolce F, Palicelli A, Ascani S, Morini A, Tumiati D, Mereu F, Zuliani AL, Nardecchia M, Gatto F, Zanni M, Giunta A. Gastrectomy with or without Complete Omentectomy for Advanced Gastric Cancer: A Meta-Analysis. *Medicina (Kaunas)* 2022; **58** [PMID: 36143918 DOI: 10.3390/medicina58091241]

19 **Chen F**, Chi J, Liu Y, Fan L, Hu K. Impact of preoperative sarcopenia on postoperative complications and prognosis of gastric cancer resection: A meta-analysis of cohort studies. *Arch Gerontol Geriatr* 2022; **98**: 104534 [PMID: 34601314 DOI: 10.1016/j.archger.2021.104534]

20 **Li Z**, Liu ZM, Xu BH. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer. *Eur Rev Med Pharmacol Sci* 2018; **22**: 8281-8287 [PMID: 30556868 DOI: 10.26355/eurrev\_201812\_16525]

21 **Jung K**, Kim DH, Seo HI, Gong EJ, Bang CS. Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis. *Helicobacter* 2021; **26**: e12774 [PMID: 33400830 DOI: 10.1111/hel.12774]

22 **Yao K**, Ma Y, Ma W, Hu J, Wang C, Chen J, Zhang J, Hua L, Ren X. Shenqifuzheng injection combined with chemotherapy in the treatment of advanced gastric cancer: a systematic review and meta-analysis. *J Cancer Res Ther* 2014; **10 Suppl 1**: 70-74 [PMID: 25207896 DOI: 10.4103/0973-1482.139768]

23 **Li J**, Wu M, Tian Q, Xie G, Hu Y, Meng Q, Zhang M. The clinical value of Fufangkushen injection in the treatment of stomach cancer: a meta-analysis. *J Cancer Res Ther* 2014; **10 Suppl 1**: 42-45 [PMID: 25207890 DOI: 10.4103/0973-1482.139755]

24 **Wang JF**, Zhang SZ, Zhang NY, Wu ZY, Feng JY, Ying LP, Zhang JJ. Laparoscopic gastrectomy versus open gastrectomy for elderly patients with gastric cancer: a systematic review and meta-analysis. *World J Surg Oncol* 2016; **14**: 90 [PMID: 27030355 DOI: 10.1186/s12957-016-0859-8]

25 **Koyyada A**. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. *Therapie* 2021; **76**: 13-21 [PMID: 32718584 DOI: 10.1016/j.therap.2020.06.019]

26 **Pietrantonio F**, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *J Clin Oncol* 2019; **37**: 3392-3400 [PMID: 31513484 DOI: 10.1200/JCO.19.01124]

27 **Schwingshackl L**, Schwedhelm C, Galbete C, Hoffmann G. Adherence to Mediterranean Diet and Risk of Cancer: An Updated Systematic Review and Meta-Analysis. *Nutrients* 2017; **9** [PMID: 28954418 DOI: 10.3390/nu9101063]

28 **Ning FL**, Zhang CD, Wang P, Shao S, Dai DQ. Endoscopic resection versus radical gastrectomy for early gastric cancer in Asia: A meta-analysis. *Int J Surg* 2017; **48**: 45-52 [PMID: 28987558 DOI: 10.1016/j.ijsu.2017.09.068]

29 **Jia Z**, Zheng M, Jiang J, Cao D, Wu Y, Zhang Y, Fu Y, Cao X. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. *BMC Cancer* 2022; **22**: 155 [PMID: 35135494 DOI: 10.1186/s12885-022-09222-y]

30 **Cowling J**, Gorman B, Riaz A, Bundred JR, Kamarajah SK, Evans RPT, Singh P, Griffiths EA. Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis. *J Gastrointest Cancer* 2021; **52**: 41-56 [PMID: 32959118 DOI: 10.1007/s12029-020-00519-4]

31 **Wöhrer SS**, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. *Ann Oncol* 2004; **15**: 1585-1595 [PMID: 15520058 DOI: 10.1093/annonc/mdh422]

32 **Zwager LW**, Bastiaansen BAJ, Montazeri NSM, Hompes R, Barresi V, Ichimasa K, Kawachi H, Machado I, Masaki T, Sheng W, Tanaka S, Togashi K, Yasue C, Fockens P, Moons LMG, Dekker E. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis. *Gastroenterology* 2022; **163**: 174-189 [PMID: 35436498 DOI: 10.1053/j.gastro.2022.04.010]

33 **Ding J**, Liao GQ, Liu HL, Liu S, Tang J. Meta-analysis of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer. *J Surg Oncol* 2012; **105**: 297-303 [PMID: 21952834 DOI: 10.1002/jso.22098]

34 **Yang Y**, Gao P, Song Y, Sun J, Chen X, Zhao J, Ma B, Wang Z. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: A meta-analysis. *Eur J Surg Oncol* 2016; **42**: 1176-1182 [PMID: 27293109 DOI: 10.1016/j.ejso.2016.05.029]

35 **Li S**, Gao J, Xu Q, Zhang X, Huang M, Dai X, Huang K, Liu L. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors. *Front Immunol* 2021; **12**: 693314 [PMID: 34177954 DOI: 10.3389/fimmu.2021.693314]

36 **Li K**, Wang D, Zhang X, Yang J, Chen X. Efficacy of early enteral nutrition versus total parenteral nutrition for patients with gastric cancer complicated with diabetes mellitus: A systematic review and meta-analysis. *Nutr Diet* 2022; **79**: 129-139 [PMID: 35233912 DOI: 10.1111/1747-0080.12721]

37 **Shimada H**, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. *Gastric Cancer* 2014; **17**: 26-33 [PMID: 23572188 DOI: 10.1007/s10120-013-0259-5]

38 **Shen M**, Wang H, Wei K, Zhang J, You C. Five common tumor biomarkers and CEA for diagnosing early gastric cancer: A protocol for a network meta-analysis of diagnostic test accuracy. *Medicine (Baltimore)* 2018; **97**: e0577 [PMID: 29742692 DOI: 10.1097/MD.0000000000010577]

39 **Zhang C**, Hou W, Huang J, Yin S, Wang P, Zhang Z, Tan Y, Xu H. Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta-analysis. *J Cell Biochem* 2019; **120**: 14486-14498 [PMID: 31050365 DOI: 10.1002/jcb.28708]

40 **Sun P**, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. *Br J Surg* 2009; **96**: 26-33 [PMID: 19016271 DOI: 10.1002/bjs.6408]

41 **Li HZ**, Chen JX, Zheng Y, Zhu XN. Laparoscopic-assisted versus open radical gastrectomy for resectable gastric cancer: Systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. *J Surg Oncol* 2016; **113**: 756-767 [PMID: 27076039 DOI: 10.1002/jso.24243]

42 **Du J**, Shen Y, Yan W, Wang J. Risk factors of lymph node metastasis in the splenic hilum of gastric cancer patients: a meta-analysis. *World J Surg Oncol* 2020; **18**: 233 [PMID: 32873315 DOI: 10.1186/s12957-020-02008-1]

43 **Hiramatsu Y**, Takeuchi H, Goto O, Kikuchi H, Kitagawa Y. Minimally Invasive Function-Preserving Gastrectomy with Sentinel Node Biopsy for Early Gastric Cancer. *Digestion* 2019; **99**: 14-20 [PMID: 30554230 DOI: 10.1159/000494407]

44 **McCulloch P**, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. *Cochrane Database Syst Rev* 2004: CD001964 [PMID: 15495024 DOI: 10.1002/14651858.CD001964.pub2]

**Footnotes**

**Institutional review board statement:** The study was approved by Ethics Committee of The First Affiliated Hospital of the University of South China.

**Informed consent statement:** The data used in the study were not involved in the patients’ privacy information, so the informed consent was waived by the Ethics Committee of The First Affiliated Hospital of University of South China. All patient data obtained, recorded, and managed only used for this study, without any harm to the patient.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 6, 2023

**First decision:** April 19, 2023

**Article in press:** May 24, 2023

**Specialty type:** Emergency Medicine

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Matysiak-Budnik T, France; Surial B, Switzerland **S-Editor:** GongZM **L-Editor:** A **P-Editor:** Cai YX

**Table 1 Comparison of general data in each group**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Items** | **Category** | **Radical resection group (*n* = 46)** | **Palliative group (*n* = 43)** | ***t*/*χ*2** | ***P* value** |
| Age (yr) |  | 69.7 ± 10.2 | 70.3 ± 10.5 | 0.273 | 0.785 |
| Gender | Male | 26 | 25 | 0.952 | 0.877 |
| Female | 20 | 18 |
| Pathological type | Adenocarcinoma | 18 | 16 | 0.719 | 0.869 |
| Mucus adenocarcinoma | 14 | 12 |
| Signet ring cell carcinoma | 11 | 10 |
| Non-adenocarcinoma | 3 | 5 |
| Tumor location | Whole stomach | 9 | 8 | 0.186 |  0.979 |
| Lower | 18 | 16 |
| Middle | 12 | 11 |
| Upper | 7 | 8 |

**Table 2 Comparison of the patients’ relevant indicators between the two groups (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | **Palliative group (*n* = 43)** | **Radical resection group (*n* = 46)** | ***t*** | ***P* value** |
| Operation time (min) | 275.32 ± 29.45 | 281.34 ± 22.67 | 1.085 | 0.281 |
| Intraoperative blood transfusion volume (mL) | 356.45 ± 54.87 | 286.0 ± 42.43 | 6.801 | < 0.001 |
| Postoperative hospitalization duration time (d) | 14.54 ± 3.37 | 13.43 ± 3.22 | 1.589 | 0.116 |
| Anal exhaust time (d) | 6.54 ± 1.43 | 4.62 ± 1.35 | 6.516 | < 0.001 |
| Off-bed activity time (d) | 9.36 ± 1.38 | 6.87 ± 1.23 | 8.998 | < 0.001 |

**Table 3 Comparison of the patients’ incidence rate of postoperative complications between the two groups, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | **Palliative group (*n* = 43)** | **Radical resection group (*n* = 46)** | ***χ*2** | ***P* value** |
| Postoperative bleeding | 2 (4.65) | 3 (6.52) | - | - |
| Duodenal stump rupture | 2 (4.65) | 2 (4.35) | - | - |
| Anastomotic obstruction | 1 (2.32) | 3 (6.52) | - | - |
| Intestinal obstruction | 3 (4.35) | 2 (4.35) | - | - |
| Abdominal effusion | 2 (4.65) | 1 (2.17) | - | - |
| Reflux gastritis | 2 (4.65) | 3 (6.52) | - | - |
| Incision infection | 1 (2.32) | 3 (6.52) | - | - |
| Overall incidence rate | 12 (27.91) | 17 (39.96) | 0.494 | 0.363 |

**Table 4 Comparison of the patients’ relevant indicators of postoperative immune function between the two groups (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Index of correlation** | **Palliative group (*n* = 43)** | **Radical resection group (*n* = 46)** | ***t*** | ***P* value** |
| CD3+ (%) | Pre-operation | 53.72 ± 3.61 | 52.13 ± 4.21 | 1.906 | 0.059 |
| Post-operation | 50.12 ± 2.32 | 63.52 ± 5.81 | 14.10 | 0.043 |
| CD4+ (%) | Pre-operation | 31.92 ± 2.83 | 30.81 ± 3.11 | 1.857 | 0.067 |
| Post-operation | 28.32 ± 2.46 | 40.34 ± 3.01 | 20.54 | 0.036 |
| CD8+ (%) | Pre-operation | 25.32 ± 2.13 | 25.34 ± 2.04 | 1.589 | 0.085 |
| Post-operation | 27.24 ± 2.05 | 25.22 ± 2.25 | 4.417 | 0.033 |
| CD4+/CD8+ | Pre-operation | 1.34 ± 0.32 | 1.32 ± 0.33 | 0.289 | 0.773 |
| Post-operation | 1.25 ± 0.34 | 1.63 ± 0.43 | 4.603 | 0.065 |
| CD3+/HLADR+ | Pre-operation | 7.23 ± 2.53 | 7.52 ± 2.62 | 1.572 | 0.658 |
| Post-operation | 6.35 ± 2.84 | 8.63 ± 3.14 | 1.767 | 0.023 |
| IgG | Pre-operation | 11.13 ± 1.58 | 11.27 ± 1.27 | 0.548 | 0.664 |
| Post-operation | 14.68 ± 2.28 | 18.35 ± 2.16 | 5.256 | 0.037 |
| IgM | Pre-operation | 3.24 ± 0.32 | 3.21 ± 0.28 | 0.363 | 0.846 |
| Post-operation | 3.56 ± 3.19 | 3.87 ± 0.53 | 3.292 | 0.016 |

**Table 5 Comparison of the patients’ levels of postoperative tumor markers and inflammatory factors between the two groups (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Index of correlation** | **Palliative group (*n* = 43)** | **Radical resection group (*n* = 46)** | ***t*** | ***P* value** |
| CEA (ng/mL) | Pre-operation | 38.63 ± 3.48 | 38.63 ± 3.48 | 0.413 | 0.753 |
| Post-operation | 15.36 ± 1.61 | 7.72 ± 0.72 | 4.974 | 0.003 |
| CA199 (U/mL) | Pre-operation | 83.63 ± 5.64 | 82.72 ± 5.82 | 0.359 | 0.645 |
| Post-operation | 33.27 ± 4.39 | 18.57 ± 3.15 | 3.292 | 0.012 |
| CA125 (U/mL) | Pre-operation | 65.34 ± 4.54 | 64.43 ± 4.68 | 0.931 | 0.354 |
| Post-operation | 40.33 ± 3.24 | 34.34 ± 3.66 | 8.153 | 0.002 |
| IL-6 (pg/mL) | Pre-operation | 44.72 ± 7.32 | 44.76 ± 7.32 | 0.724 | 0.463 |
| Post-operation | 36.87 ± 2.77 | 27.47 ± 2.59 | 2.472 | 0.015 |
| IL-17 (pg/mL) | Pre-operation | 64.32 ± 5.96 | 62.46 ± 7.48 | 0.934 | 0.723 |
| Post-operation | 54.63 ± 6.27 | 43.14 ± 5.69 | 2.772 | 0.028 |
| TNF-α (pg/mL) | Pre-operation | 17.44 ± 2.35 | 16.57 ± 2.28 | 0.513 | 0.674 |
| Post-operation | 9.36 ± 0.87 | 5.58 ± 0.46 | 4.562 | 0.013 |

CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; CA125: Carbohydrate antigen 125; IL-6: Interleukin-6 IL-17: Interleukin-17; TNF-α: Tumor necrosis factor α.

**Table 6 Comparison of the patient’s postoperative quality of life between the two groups, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Item** | **Palliative group (*n* = 43)** | **Radical resection group (*n* = 46)** | ***t*** | ***P* value** |
| Efficacy | CR | 21 (48.84) | 35 (76.09) | - | - |
| PR | 8 (18.60) | 8 (17.39) | - | - |
| SD | 10 (23.26) | 3 (6.52) | - | - |
| PD | 4 (9.30) | 0 (0.00) | - | - |
| ORR | 29 (67.44) | 43 (93.48) | 0.004 | 0.044 |
| DCR | 39 (90.69) | 46 (100.00) | 0.109 | 0.034 |
| KPS score | Improved | 23 (50.00) | 10 (23.26) | 0.017 | 0.009 |
| Stable | 14 (30.43) | 15 (34.88) | 0.825 | 0.655 |
| Ineffective | 9 (19.57) | 18 (41.86) | 0.039 | 0.022 |
| Effective | 37 (80.43) | 25 (58.14) | 0.039 | 0.022 |

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

**Table 7 Comparison of the patient’s postoperative survival rate between the two groups, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Item** | **Palliative group (*n* = 43)** | **Radical resection group (*n* = 46)** | ***t*** | ***P* value** |
| Follow-up 6 mo | Recurrence rate  | 5 (11.63) | 3 (6.52) | 0.400 | 0.638 |
| Survival rate | 39 (90.71) | 46 (100.00) | 0.109 | 0.034 |
| Follow-up 1 year | Recurrence rate  | 6 (13.95) | 1 (2.17) | 0.095 | 0.039 |
| Survival rate | 34 (79.07) | 45 (97.83) | 0.0134 | 0.005 |
| Follow-up 2 year | Recurrence rate  | 9 (20.93) | 1 (2.17) | 0.013 | 0.005 |
| Survival rate | 27 (62.79) | 40 (86.96) | 0.017 | 0.008 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**